公开(公告)号：US20240351997A1

公开(公告)日：2024-10-24

申请号：US18580154

申请日：2022-07-28

申请人： SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD.

发明人： Xiaoxia YAN ,  Guanxin HUANG ,  Wei JU ,  Daqing SUN

IPC分类号： C07D401/12 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  C07D239/42 ,  C07D401/14 ,  C07D403/12 ,  C07D417/12 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08

CPC分类号： C07D401/12 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  C07D239/42 ,  C07D401/14 ,  C07D403/12 ,  C07D417/12 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08

摘要： Disclosed are a compound serving as a PARP7 inhibitor, and a use thereof in preparing a drug for treating relevant diseases. Specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The compound can be used for treating cancer.

公开(公告)号：US20240317708A1

公开(公告)日：2024-09-26

申请号：US18573802

申请日：2022-06-30

申请人： ZEDIRA GMBH

发明人： Ralf PASTERNACK ,  Christian BÜCHOLD ,  Martin HILS ,  Martin STIELER ,  Uwe GERLACH

IPC分类号： C07D401/12 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4748 ,  A61K31/497 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  C07D213/75 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D513/04

CPC分类号： C07D401/12 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4748 ,  A61K31/497 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  C07D213/75 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D513/04

摘要： The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use for the prophylaxis and treatment of diseases associated with transglutaminases, in particular transglutaminase 2.

公开(公告)号：US20240316043A1

公开(公告)日：2024-09-26

申请号：US18612647

申请日：2024-03-21

申请人： University of Tennessee Research Foundation

发明人： Duane Miller ,  Lawrence Pfeffer ,  Yali He ,  Yinan Wang ,  Chuan Yang

IPC分类号： A61K31/4995 ,  A61K31/495 ,  A61P35/00 ,  C07D487/08

CPC分类号： A61K31/4995 ,  A61K31/495 ,  A61P35/00 ,  C07D487/08

摘要： The present disclosure related to compounds of Formula (I):




stereoisomers thereof, prodrugs thereof, and pharmaceutically acceptable salts thereof. The present disclosure also relates to uses of the compounds, including to treat cancer in a subject.

公开(公告)号：US20240316034A1

公开(公告)日：2024-09-26

申请号：US18655194

申请日：2024-05-03

申请人： Emory University

发明人： Dennis C. Liotta ,  Edgars Jecs ,  Robert James Wilson ,  Huy Hoang Nguyen ,  Michelle Bora Kim ,  Lawrence Wilson ,  Eric Miller ,  Yesim Altas Tahirovic ,  Valarie Truax

IPC分类号： A61K31/4725 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/5377 ,  A61K31/541 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

CPC分类号： A61K31/4725 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/5377 ,  A61K31/541 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

摘要： The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.

公开(公告)号：US20240270747A1

公开(公告)日：2024-08-15

申请号：US18523284

申请日：2023-11-29

申请人： Genentech, Inc.

发明人： James John CRAWFORD ,  Daniel Fred ORTWINE ,  BinQing WEI ,  Wendy B. YOUNG

IPC分类号： C07D487/04 ,  A61K9/20 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06 ,  A61P35/00 ,  A61P37/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/08 ,  C07D487/14 ,  C07D495/04 ,  C07D495/14 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61K9/20 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06 ,  A61P35/00 ,  A61P37/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/08 ,  C07D487/14 ,  C07D495/04 ,  C07D495/14 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

摘要： Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

公开(公告)号：US20240239775A1

公开(公告)日：2024-07-18

申请号：US18555470

申请日：2022-04-18

申请人： QINGDAO RUIJI MEDICAL TECHNOLOGY CO., LTD.

发明人： Ning JIAO ,  Xiaodong DOU ,  Tongyu HUO ,  Lingyu SU ,  Xinyi ZHAO ,  Yingjie HUANG ,  Yameng LIU

IPC分类号： C07D409/14 ,  A61K31/438 ,  A61K31/4535 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/551 ,  A61P35/00 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D471/10 ,  C07D487/08

CPC分类号： C07D409/14 ,  A61K31/438 ,  A61K31/4535 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/551 ,  A61P35/00 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D471/10 ,  C07D487/08

摘要： The present invention relates to a compound capable of being used as an FXR regulator, a pharmaceutically acceptable salt or ester, a stereoisomer, a tautomer, a geometric isomer, a prodrug, a hydrate, a solvate or a crystalline form thereof, a metabolite form of same, or any combination or mixture of same, and also relates to a preparation method therefor, a pharmaceutical composition thereof and the use thereof.

公开(公告)号：US20240189308A1

公开(公告)日：2024-06-13

申请号：US18417725

申请日：2024-01-19

申请人： Mirum Pharmaceuticals, Inc.

发明人： Thomas JAECKLIN ,  Alejandro DORENBAUM

IPC分类号： A61K31/4995 ,  A61K31/554 ,  A61K31/7042 ,  A61P1/16 ,  A61P17/04 ,  G01N33/68

CPC分类号： A61K31/4995 ,  A61K31/554 ,  A61K31/7042 ,  A61P1/16 ,  A61P17/04 ,  G01N33/6893 ,  G01N2800/085

摘要： Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg/kg/day.

公开(公告)号：US20240148745A1

公开(公告)日：2024-05-09

申请号：US18549457

申请日：2022-03-09

申请人： FONDAZIONE CENTRO SAN RAFFAELE ,  INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE ,  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  SORBONNE UNIVERSITE ,  WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  HEINRICH HEINE UNIVERSITY DÜSSELDORF ,  UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ ,  THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY ,  ISTITUTO SUPERIORE DI SANITÀ ,  CONSIGLIO NAZIONALE DELLE RICERCHE ,  IRBM S.P.A.

发明人： Gianvito MARTINO ,  Paola PANINA ,  Brahim NAIT-OUMESMAR ,  Anne BARON-VAN EVERCOOREN ,  Tanja KUHLMANN ,  Sergio BARANZINI ,  Norbert GOEBELS ,  Frauke ZIPP ,  Nicholas HANUSCHECK ,  Jack ANTEL ,  Cristina AGRESTI ,  Maria Pia ABBRACCHIO ,  Ivano EBERINI ,  Chiara PARRAVICINI ,  Stefania OLLA ,  Alberto BRESCIANI

IPC分类号： A61K31/5377 ,  A61K31/405 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/5025 ,  A61K31/55 ,  A61P25/28 ,  G01N33/50

CPC分类号： A61K31/5377 ,  A61K31/405 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/5025 ,  A61K31/55 ,  A61P25/28 ,  G01N33/5058

摘要： The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. The compounds have been identified through methods of pharmacological screening of a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.

公开(公告)号：US20240139314A1

公开(公告)日：2024-05-02

申请号：US18486563

申请日：2023-10-13

申请人： Myeloid Therapeutics, Inc.

发明人： Daniel GETTS ,  Yuxiao WANG

IPC分类号： A61K39/395 ,  A61K31/407 ,  A61K31/4709 ,  A61K31/4995 ,  C07K14/47 ,  C07K14/705 ,  C07K14/735 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N15/85

CPC分类号： A61K39/3955 ,  A61K31/407 ,  A61K31/4709 ,  A61K31/4995 ,  C07K14/47 ,  C07K14/70535 ,  C07K14/70596 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/303 ,  C07K16/32 ,  C12N15/85 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/50 ,  C12N2800/107

摘要： The present disclosure provides compositions and methods for making and using engineered myeloid cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, wherein the chimeric receptor is encoded by a recombinant nucleic acid.

公开(公告)号：US11903941B2

公开(公告)日：2024-02-20

申请号：US17543505

申请日：2021-12-06

申请人： Oyster Point Pharma, Inc.

发明人： Douglas Michael Ackermann, Jr. ,  James Loudin ,  Kenneth J. Mandell

IPC分类号： A61K31/4995 ,  A61K31/4439 ,  A61K45/06 ,  A61K9/00 ,  A61K31/439 ,  A61K31/4427 ,  A61K9/08 ,  A61K31/4985

CPC分类号： A61K31/4995 ,  A61K9/007 ,  A61K9/0043 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/439 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/4985 ,  A61K45/06

摘要： Described herein are methods and pharmaceutical formulations for treating dry eye disease.